What this study is
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.
What's being tested
- Cabozantinib
Intervention · DRUG
- Zanzalintinib
Intervention · DRUG
- Atezolizumab
Intervention · DRUG
- Nivolumab
Intervention · DRUG
- Abiraterone
Intervention · DRUG
- Prednisone
Intervention · DRUG
- Enzalutamide
Intervention · DRUG
All interventions
Administered as specified in the parent study.
Study details
- Sponsor
- Exelixis
- Conditions
- Cancer · Renal Cell Carcinoma (RCC) · Pancreatic Neuroendocrine Tumors (pNET) · Extra-Pancreatic NET (epNET) · Hepatocellular Carcinoma (HCC) · Differentiated Thyroid Cancer (DTC) · Non-Clear Cell Renal Cell Carcinoma (nccRCC) · Colorectal Cancer · Prostate Cancer
- Enrolling
- 5,000 people
- Starts
- 2026-07-30
- Est. completion
- 2030-05-31
- Design
- Open-label, single group, Phase 3
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers Not acceptedYou may qualify if
- Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation/withdrawal criteria).
- Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.
- Able to comply with the long-term extension study protocol as determined by the investigator.
- Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.
You can't join if
- Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.
- Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.
- Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.
- Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).
- Concurrent participation in any therapeutic clinical trial (other than the parent study).
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (4)
4 openNew York Cancer and Blood Specialists
Bay Shore, New York, United States
Greater Dayton Cancer Center
Kettering, Ohio, United States
The West Clinic
Memphis, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Study team
Sponsor
Exelixis
Study ID EXEL-LTE-1
Study director
Medical Director
Exelixis
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.